Respiration
February 12, 2026
1 min readIP Score 9/10
Photodynamic Therapy for Central Early-Stage Lung Cancer: A Retrospective Comparative Study of Photofrin, Chlorin e6, and Foscan
Sondermann T, Darwiche K, Freitag L, et al.
Abstract
Introduction: Photodynamic therapy (PDT) is a minimally invasive, organ-preserving treatment option for patients with centrally located early-stage non-small cell lung cancer. While first-generation photosensitizers such as Photofrin are well established, second-generation agents like Chlorin e6 offer improved pharmacokinetics and potentially better clinical outcomes. The objective of this study was to assess the safety profile and therapeutic efficacy of different photosensitizers used in PDT for centrally located early-stage lung cancer (CELC).
Methods: We retrospectively analyzed 62 CELC lesions in 36 patients treated with PDT between 2015 and 2024. Patients received one of three photosensitizers - Photofrin, Chlorin e6, or Foscan - followed by bronchoscopic light activation. Outcomes included complete remission (CR), local tumor control (LTC), disease-free survival (DFS), and treatment-related adverse events.
Results: CR rates were 87.5% (28/32) for Chlorin e6, 100% (3/3) for Foscan, and 68.8% (22/32) for Photofrin, with a nonsignificant trend favoring Chlorin e6 over Photofrin (p = 0.13). Mean DFS was longest in the Chlorin e6 group (43.3 months; 95% CI: 32.5-54.1), followed by Photofrin (24.0 months; 95% CI: 17.2-30.8) and Foscan (7.3 months; 95% CI: 6.3-8.4). Durable LTC was achieved in 84.1% of lesions without need for escalation to systemic or surgical treatment. Chlorin e6 demonstrated a more favorable safety profile than Photofrin.
Conclusion: PDT is a safe and effective treatment modality for CELC, achieving high rates of LTC. Among the evaluated photosensitizers, Chlorin e6 showed a favorable balance of efficacy and safety.
This case highlights the diagnostic and management challenges of refractory multisystem sarcoidosis progressing over a two-year period despite advanced biologic therapy.
Clinicians should note that the presence of targetable mutations in non-small cell lung cancer with malignant pleural disease is not associated with improved survival, based on the findings from this study.
Shape-sensing robotic-assisted bronchoscopy achieved a strict diagnostic yield of 70.2% with a low pneumothorax rate of 3.3%, demonstrating that earlier tissue diagnosis of very small pulmonary nodules is feasible and safe for clinical practice.
Up nextJournal of Thoracic DiseaseOct 30, 2026Read
This study introduces ultrasound-guided trans-cannula cryobiopsy of supraclavicular lymph nodes as a novel superficial lymph node approach for tissue acquisition in 10 consecutive patients, though specific numeric success or safety results were not provided in the abstract.
Active infection is not an absolute contraindication to endobronchial valve placement, but positive pressure ventilation significantly increases clinical failure odds with an aOR of 3.00 at P < 0.001.